Featured Research

from universities, journals, and other organizations

Regular statin use is associated with a reduced risk of developing rheumatoid arthritis

Date:
September 8, 2010
Source:
Public Library of Science
Summary:
There is an association between taking statins (lipid lowering drugs), and reduced risk of developing the chronic inflammatory disease, rheumatoid arthritis.

There is an association between taking statins (lipid lowering drugs), and reduced risk of developing the chronic inflammatory disease, rheumatoid arthritis. These are the findings of a study by Gabriel Chodick and colleagues, published in this week's PLoS Medicine.

The researchers conducted a retrospective cohort study among the 1.8-million members of Maccabi Healthcare Services (a health maintenance organization [HMO]) in Israel to identify adults who regularly took statins and did not have rheumatoid arthritis. Using Maccabi's large automated datasets, the researchers then analyzed diagnostic codes to assess the incidence of newly diagnosed rheumatoid arthritis in this group between 1998 and 2007. To assess any potential bias, the researchers also examined any possible association between persistent statin use and the development of osteoarthritis, a common degenerative joint disease that is unlikely to be affected by statin use.

During the study follow-up period, there were 2,578 incident cases of rheumatoid arthritis and 17,878 incident cases of osteoarthritis. The unadjusted rate of rheumatoid arthritis among patients who did not persistently take statins was 51% higher than that of patients who used statins for at least 80% of the follow-up period. After adjusting for other possible confounders, patients who persistently took statins had a lower risk (risk ratio of 0.58) of developing rheumatoid arthritis compared with patients who did not persistently take statins. There was only a small short term decrease in risk ratio in patients taking statins and the development of osteoarthritis. (hazard ratio of 0.85)

This work needs to be confirmed in other populations before its clinical significance, if any, is clear. As the authors conclude: "Larger, systematic, controlled, prospective studies with high efficacy statins, particularly in younger adults who are at increased risk of rheumatoid arthritis, are needed to confirm these findings and to clarify the exact nature of the biological relationship between adherence to statin therapy and the incidence of rheumatoid arthritis."


Story Source:

The above story is based on materials provided by Public Library of Science. Note: Materials may be edited for content and length.


Journal Reference:

  1. Chodick et al. Persistence with Statins and Onset of Rheumatoid Arthritis: A Population-Based Cohort Study. PLoS Medicine, 2010; 7 (9): e1000336 DOI: 10.1371/journal.pmed.1000336

Cite This Page:

Public Library of Science. "Regular statin use is associated with a reduced risk of developing rheumatoid arthritis." ScienceDaily. ScienceDaily, 8 September 2010. <www.sciencedaily.com/releases/2010/09/100907171634.htm>.
Public Library of Science. (2010, September 8). Regular statin use is associated with a reduced risk of developing rheumatoid arthritis. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2010/09/100907171634.htm
Public Library of Science. "Regular statin use is associated with a reduced risk of developing rheumatoid arthritis." ScienceDaily. www.sciencedaily.com/releases/2010/09/100907171634.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins